Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,166.51 -16.11 (-1.36%)

Official Closing Price Updated: 4:10 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗

Today 17:12 EDT

Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate.

Via The Motley Fool

3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years ↗

Today 16:40 EDT

These stocks have rewarded their shareholders with significant dividend increases in recent years and are likely to continue doing so in the future.

Via The Motley Fool

Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)? ↗

Today 16:13 EDT

FHLC offers broader sector exposure at a 0.08% expense ratio, compared with IBB's concentrated biotech focus at 0.44%, but IBB delivered stronger 1-year returns despite higher volatility.

Via The Motley Fool

Topics ETFs

Eli Lilly Reports Earnings on Oct. 29. Here's Why the Retatrutide Story Matters More Than the Quarter. ↗

Today 10:20 EDT

Eli Lilly's next big growth driver could be bigger than Zepbound.

Via The Motley Fool

Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued. ↗

Today 5:30 EDT

This pharma stock has climbed in the triple digits in recent years.

Via The Motley Fool

Will Eli Lilly Do a Stock Split Before the End of 2026? ↗

Today 2:20 EDT

Eli Lilly's stock price is comfortably above $1,000, and management could easily justify doing a stock split.

Via The Motley Fool

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 12, 2026

AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.

Via The Motley Fool

4 Healthcare Stocks Worth Owning for the Next Decade ↗

October 12, 2026

Two healthcare stocks that are leading their niches, and two that investors aren't giving enough credit to in the same niches.

Via The Motley Fool

Topics Intellectual Property

Biogen (BIIB) Stock Is Up, What You Need To Know

October 12, 2026

What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neut...

Via StockStory

Topics Earnings

This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock ↗

October 12, 2026

Eli Lilly isn't content with the success of its current GLP-1 drugs; it's on the hunt for even better weight loss solutions.

Via The Motley Fool

Own Both VOO and QQQM? You May Be Buying the Same Stocks Twice. ↗

October 12, 2026

Major index funds are heavily concentrated with the same few tech names. How can investors avoid overlapping stocks?

Via The Motley Fool

Topics ETFs

Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. ↗

October 12, 2026

Oppenheimer raised Viking Therapeutics' price target to $120, citing strong trial data, and an improving probability of success for its key drug.

Via The Motley Fool

Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next. ↗

October 12, 2026

Lilly's recent retreat isn't a sign of a broken investment thesis.

Via The Motley Fool

Topics Earnings

2 S&P 500 Stocks to Own for Decades and 1 We Find Risky

October 12, 2026

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Via StockStory

Topics Bonds Stocks

Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP? ↗

October 11, 2026

Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next.

Via The Motley Fool

Topics ETFs

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? ↗

October 11, 2026

IBB has delivered stronger returns than IYH but with dramatically sharper swings in both directions. Here is how to decide which trade-off fits your portfolio.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE? ↗

October 11, 2026

One offers broad diversification at 0.08% cost, while the other targets concentrated biotech growth with higher volatility.

Via The Motley Fool

Topics ETFs

Prediction: My Top 2 Stocks to Buy Now Will Outperform the Stock Market Over the Next Decade ↗

October 11, 2026

These elite businesses could help you build lasting wealth.

Via The Motley Fool

Topics Artificial Intelligence

As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze ↗

October 11, 2026

The weight-loss drugs are growing in popularity and altering consumer behavior in significant ways.

Via The Motley Fool

Better Pharma ETF: iShares IHE vs. State Street XPH ↗

October 10, 2026

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.

Via The Motley Fool

Topics ETFs

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? ↗

October 10, 2026

Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

Via The Motley Fool

1 Healthcare Stock Worth Your Attention and 2 We Turn Down

October 09, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...

Via StockStory

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument. ↗

October 08, 2026

UBS analyst Michael Yee called Novo Nordisk a value trap, but still sees a turnaround playing out over time.

Via The Motley Fool

2 Growth Stocks to Buy in October ↗

October 08, 2026

Grail and Veeva Systems could be well insulated from near-term headwinds.

Via The Motley Fool

Stay informed with the top movers within the S&P500 index on Thursday. ↗

October 08, 2026

Via Chartmill

Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare Platform ↗

October 08, 2026

Eli Lilly's obesity lead is only the starting point. See what its pipeline, manufacturing build-out, pricing pressure, and earnings trajectory could mean for the stock's next chapter.

Via The Motley Fool

Which S&P500 stocks are gapping on Thursday? ↗

October 08, 2026

Via Chartmill

Only 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI ↗

October 08, 2026

Stansberry Research's Whitney Tilson argues record highs mask a bifurcated market, favoring Joby Aviation, Casey's General Stores, and Eli Lilly as value picks outside the AI trade.

Via MarketBeat

Topics Artificial Intelligence

Pfizer Trades Under 10 Times Forward Earnings With a Yield Near 6%. Here's What History Says Happens Next. ↗

October 08, 2026

Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet.

Via The Motley Fool

Topics Intellectual Property

Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound ↗

October 07, 2026

The company is far from a one-trick pony.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.